供应商：上海经科化学科技有限公司
供应商：上海经科化学科技有限公司 供应商：上海经科化学科技有限公司 供应商：上海经科化学科技有限公司 供应商：上海经科化学科技有限公司
服务热线：400-0199-638
服务热线：400-0199-638 服务热线：400-0199-638 服务热线：400-0199-638 服务热线：400-0199-638
QQ:472482400(上海经科）
QQ:472482400(上海经科）QQ:472482400(上海经科）QQ:472482400(上海经科）QQ:472482400(上海经科）
微信号：shjkchem
微信号：shjkchem 微信号：shjkchem 微信号：shjkchem 微信号：shjkchem
活动：消费积分可换充值卡！
活动：消费积分可换充值卡！活动：消费积分可换充值卡！活动：消费积分可换充值卡！活动：消费积分可换充值卡！
本试剂(6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺)
仅供科研实验使用,不得用于其他用途！
本试剂(6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺)
仅供科研实验使用,不得用于其他用途！本试剂(6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺)
仅供科研实验使用,不得用于其他用途！本试剂(6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺)
仅供科研实验使用,不得用于其他用途！本试剂(6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺)
仅供科研实验使用,不得用于其他用途！本试剂(6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺)
仅供科研实验使用,不得用于其他用途！
简介：
货 号：LC2-V-9366
名 称：6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺
别 名：VX-702 Free Base
C A S ：745833-23-2
分子量：404.32
分子式：C19H12F4N4O2
纯 度：HPLC/TLC:>99%
说 明：Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.
文 献简介：
货 号：LC2-V-9366
名 称：6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺
别 名：VX-702 Free Base
C A S ：745833-23-2
分子量：404.32
分子式：C19H12F4N4O2
纯 度：HPLC/TLC:>99%
说 明：Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.
文 献简介：
货 号货 号货 号货 号
：LC2-V-9366
名 称：6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺
别 名：VX-702 Free Base
C A S ：745833-23-2
分子量：LC2-V-9366
名 称：6-[(氨基羰基)(2,6-二氟苯基)氨基]-2-(2,4-二氟苯基)-3-吡啶甲酰胺
别 名：VX-702 Free Base
C A S ：745833-23-2
分子量
：404.32：404.32
分子式分子式
：C19H12F4N4O2：C19H12F4N4O2
纯 度纯 度
：HPLC/TLC:>99%：HPLC/TLC:>99%
说 明说 明
：Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.：Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A.
文 献文 献
：VX-702 is a second-generation, orally active mitogen-activated protein kinase (MAPK) p38 inhibitor. It is being tested for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. Ding, C. "Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome." Curr. Opin. Investig. Drugs 7: 1020-1025 (2006).p38 MAPK increases thromboxane levels by activating phospholipase A2, thus catalyzing the formation of arachidonic acid. VX-702 inhibited activation of p38 MAPK by thrombin, SFLLRN, AYPGKF and U46619 in platelets. Kuliopulos, A., et al. "Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation." Thromb. Haemost. 92: 1387-1393 (2004).VX-702 showed modest clinical efficacy and transient suppression of biomarkers of inflammation in patients with rheumatoid arthritis. Damjanov, N., et al. "Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies." Arthritis Rheum. 60: 1232-1241 (2009).：VX-702 is a second-generation, orally active mitogen-activated protein kinase (MAPK) p38 inhibitor. It is being tested for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. Ding, C. "Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome." Curr. Opin. Investig. Drugs 7: 1020-1025 (2006).p38 MAPK increases thromboxane levels by activating phospholipase A2, thus catalyzing the formation of arachidonic acid. VX-702 inhibited activation of p38 MAPK by thrombin, SFLLRN, AYPGKF and U46619 in platelets. Kuliopulos, A., et al. "Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation." Thromb. Haemost. 92: 1387-1393 (2004).VX-702 showed modest clinical efficacy and transient suppression of biomarkers of inflammation in patients with rheumatoid arthritis. Damjanov, N., et al. "Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies." Arthritis Rheum. 60: 1232-1241 (2009).
